Loading...

PODCAST

The BioCentury Show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.Don"t miss this event, every two weeks, now available as a video webcast

science life sciences

All Episodes

38:58

Ep. 120 - Canaan’s Julie Grant on building biotechs...

The BioCentury Show ·

2026/10/02

Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which Servier acquired for $2.5 billion this year. In an interview with BioCentury's Lindsay Martin, Grant discussed white spaces in women's health such as migraine and anemia, and why mid-tier acquirers like Jazz, Ipsen and Servier make smaller markets viable. She also explained why the l...

en-us

34:32

Ep. 119 - Blackstone's Galakatos on funding biotech's...

The BioCentury Show ·

2026/09/18

On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the goal of game-changing bets. Galakatos discusses Blackstone's thesis for addressing the late-stage financing gap, as Phase III programs costing more than $1 billion drive demand for large, product-based capital. He also addresses structured capital as an alternative to acquisition...

en-us

31:44

Ep. 118 - Regeneron's Gonçalo Abecasis on turning...

The BioCentury Show ·

2026/09/04

On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug discovery platform and the practical use of AI in genomics. View full story: https://www.biocentury.com/article/660697 #Genomics #DrugDiscovery #AI #GeneticMedicines #ClinicalTrials 0:00 - Introduction 1:14 - Regeneron Genetics Center 10:29 - Acting on Genetic Signals 16:57 ...

en-us

29:57

Ep. 117 - C-Path's Klaus Romero on moving genetic...

The BioCentury Show ·

2026/08/21

The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined diseases. The initiative seeks to bring form to FDA’s Plausible Mechanism Framework by standardizing how evidence and methods can be reused across therapies and patients. In conversation with Biopharma Analyst Dr. Tierney Baum on The BioCentury Show, C-Path CEO and CSO Klaus Romero ...

en-us

32:38

Ep. 116 - Ovid's Jeremy Levin on biotech in the balance

The BioCentury Show ·

2026/08/07

Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biot...

en-us

40:29

Ep. 115 - Initiate's Owens on what it takes to be...

The BioCentury Show ·

2026/07/23

As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model. Owens also discusses gaps in evidence generation for diagnostics, and closes ...

en-us

41:59

Ep. 114 - Roivant’s Matt Gline on commercial launches...

The BioCentury Show ·

2026/07/10

Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year. In conversation with Lindsay Martin on The BioCentury Show, Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its ...

en-us

35:06

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s...

The BioCentury Show ·

2026/06/25

Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and chief strategy officer, Hengrui is engaging in a range of dealmaking and using its partnerships as stepping stones toward its goal of becoming one of the top biopharma companies in the world. In conversation with Executive Editor Jeff Cranmer on The BioCent...

en-us

40:29

Ep. 112 - Chris Arendt on rebuilding Takeda for AI

The BioCentury Show ·

2026/06/18

Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development. View full story: https://www.biocentury.com/article/659807 #Artif...

en-us

36:55

Ep. 111 - McGill's Angela Genge on why ALS drug...

The BioCentury Show ·

2026/06/12

ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch. On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the firs...

en-us

37:37

Ep. 110 - Richard Pops on Three Decades in Biotech:...

The BioCentury Show ·

2026/05/28

Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have benefited from the company’s medicines. He has led PDUFA reauthorization negotiations for industry, chaired BIO, and advocated for the interests of mid-sized biotechs. As Pops prepares to retire as CEO (he will remain chairman), he spoke with B...

en-us

36:08

Ep. 109 - Mind the Gap: Karen Knudsen on Fixing...

The BioCentury Show ·

2026/05/15

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.” In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact. As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing r...

en-us

33:21

Ep. 108 - Rethinking Discovery: Chris Hollowood on...

The BioCentury Show ·

2026/05/01

A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood. Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s appro...

en-us

37:40

Ep. 107 - Forbion’s Slootweg on Europe Biotech,...

The BioCentury Show ·

2026/04/17

The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally. “We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in...

en-us

33:50

Ep. 106 - Can the U.K. Capture Biotech Value? Daniel...

The BioCentury Show ·

2026/04/03

The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving. Mahony, one of the major influential figures in U.K. biotech, is a senior partner in growth investments at Novo Holdings, and was until December chair of the U.K.’s BioIndustry Association (BIA). In conversation with BioCentury Editor in Chief Simo...

en-us

39:32

Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged...

The BioCentury Show ·

2026/03/20

As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration. View full story: https://www.biocentury.com/article/658829 ...

en-us

35:14

Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug...

The BioCentury Show ·

2026/03/06

There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower relative to the broader healthcare environment, SoftBank’s Jacqueline Fok said on The BioCentury Show. In conversation with BioCentury's Stephen Hansen, Fok, who is investment director, Life Sciences & Health Tech at SoftBank Investment Advisers, also detailed SoftBank’s inv...

en-us

40:58

Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA...

The BioCentury Show ·

2026/02/18

Caution: This episode of The BioCentury Show contains strong language. In a candid interview with BioCentury, RA Capital Managing Partner Peter Kolchinsky warns that staffing losses and growing conservatism at FDA are slowing drug development and pushing companies to launch early-stage trials outside the U.S. In conversation with BioCentury Washington Editor Steve Usdin, Kolchinsky also discusses U.S. policy headwinds, including most-favored-nation (MFN) pricing proposals and the Inflation R...

en-us

40:43

Ep. 102 - Psychiatry R&D: Steve Paul on Serendipity,...

The BioCentury Show ·

2026/02/06

With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery, selectivity and tolerability fixes are turning long-standing hypotheses into usable medicines, says veteran CNS drug developer Steven Paul. Few drug developers have had a closer view of the field’s false starts — and occasional breakthroughs — than Paul, who has moved from NIH to pharma R&D leadership and now to company building at Ka...

en-us

29:23

Ep. 101 - Why Science Stalls: Astellas CEO Naoki...

The BioCentury Show ·

2026/01/23

Why does great science so often stall before it becomes a medicine? Astellas Pharma CEO Naoki Okamura argues the bottleneck isn’t capital — it’s translation: a shortage of people, processes and platforms that can move ideas across the boundaries of biology, manufacturing, regulation and commercialization. That theme threaded through his conversation on The BioCentury Show with Executive Editor Selina Koch, surfacing most clearly in his diagnosis of what Japan’s biotech ecosystem lacks — and i...

en-us

72 results

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media